Search results for "Claudication"

showing 10 items of 47 documents

Consensus document on intermittent claudication from the Central European Vascular Forum 1st edition - Abano Terme (Italy) - May 2005 2nd revision - …

2008

Peripheral Vascular DiseasesLegtrainingTiclopidineAspirinAcetylsalicylic acidanticoagulant agentantithrombocytic agentconsensus document; intermittent claudicatio; training; antiplatelets' therapyintermittent claudicatioIntermittent ClaudicationSettore MED/11 - Malattie Dell'Apparato CardiovascolareClopidogrelantiplatelets' therapyIschemiaDisease ProgressionExercise TestHumansCarotid StenosisUltrasonography Doppler Colorconsensus documentPlatelet Aggregation Inhibitors
researchProduct

Pentoxifylline in liver ischemia and reperfusion.

2013

Pentoxifylline is a methylxanthine compound which was first filed in 1973 and registered in 1974 in the United States by Sanofi-Aventis Deustchland Gmbh for the treatment of intermittent claudication for chronic occlusive arterial disease. This methylxanthine was later discovered to be a phosphodiesterase inhibitor. Furthermore, its hemorheological properties and its function as an inhibitor of inflammatory cytokines, like TNF- α, allowed researchers to study its effects in organ ischemia and reperfusion and transplantation. Although this drug has demonstrated beneficial effects, the mechanisms by which Pentoxifylline exerts a protective effect are not fully understood. This paper focuses o…

Phosphodiesterase InhibitorsIschemiaApoptosisPharmacologyPentoxifyllineProinflammatory cytokineIschemiamedicineAnimalsHumansPhosphodiesterase inhibitorPentoxifyllinebusiness.industryTumor Necrosis Factor-alphaLiver Diseasesmedicine.diseaseIntermittent claudicationLiver TransplantationTransplantationLiverAnesthesiaReperfusion InjurySurgeryTumor necrosis factor alphamedicine.symptombusinessReperfusion injurymedicine.drugJournal of investigative surgery : the official journal of the Academy of Surgical Research
researchProduct

Peripheral artery disease: potential role of ACE-inhibitor therapy

2008

Giuseppe Coppola, Giuseppe Romano, Egle Corrado, Rosa Maria Grisanti, Salvatore NovoDepartment of Internal Medicine, Cardiovascular and Nephro-Urological Diseases, Chair of Cardiovascular Disease, University of Palermo, Palermo, ItalyAbstract: Subjects with peripheral arterial disease (PAD) of the lower limbs are at high risk for cardiovascular and cerebrovascular events and the prevalence of coronary artery disease in such patients is elevated. Recent studies have shown that regular use of cardiovascular medications, such as therapeutic and preventive agents for PAD patients, seems to be promising in reducing long-term mortality and morbidity. The angiotensin-converting-enzyme (ACE) system…

Ramiprillcsh:Diseases of the circulatory (Cardiovascular) systemmedicine.medical_specialtyPathologyACE inhibitorsEndocrinology Diabetes and MetabolismBradykininAngiotensin-Converting Enzyme InhibitorsReviewDiseaseendothelial dysfunctionCoronary artery diseasechemistry.chemical_compoundperipheral arterial diseaseInternal medicineHumansMedicinePharmacology (medical)Endothelial dysfunctionCell ProliferationSubclinical infectionPeripheral Vascular Diseasesbusiness.industryFibrinolysisPublic Health Environmental and Occupational HealthCardiovascular AgentsPeripheral artery disease ACE-inhibitorintermittent claudicationHematologyGeneral Medicinemedicine.diseaseSettore MED/11 - Malattie Dell'Apparato Cardiovascolareperipheral arterial disease.Oxidative StressTreatment OutcomeLower ExtremitychemistryCardiovascular Diseaseslcsh:RC666-701ACE-inhibitorsACE inhibitorCardiovascular agentCardiologyEndothelium VascularatherosclerosisCardiology and Cardiovascular Medicinebusinessmedicine.drugVascular Health and Risk Management
researchProduct

Statins and peripheral arterial disease: effects on claudication, disease progression, and prevention of cardiovascular events.

2006

Peripheral arterial disease (PAD) of the lower limbs is the third most important site of atherosclerotic disease alongside coronary heart disease (CHD) and cerebrovascular disease (CVD). Best medical treatment is beneficial even in patients who eventually need invasive treatment, as the safety, immediate success, and durability of intervention is greatly improved in patients who adhere to best medical treatment. In recent years, a number of studies have suggested that the ACE-inhibitor ramipril and different statins, together with antiplatelet drugs, reduce cardiovascular morbidity and mortality in PAD. Patients with PAD are really a category of patients with a very high cardiovascular risk…

Ramiprilmedicine.medical_specialtyRenal functionCoronary Diseasechemistry.chemical_compoundRisk FactorsInternal medicinemedicineHumanscardiovascular diseasesPeripheral Vascular DiseasesFramingham Risk ScoreCholesterolbusiness.industryAnticholesteremic AgentsGeneral MedicineArteriesCholesterol LDLIntermittent ClaudicationAtherosclerosisIntermittent claudicationPeripheralchemistryHemostasisCardiologyDisease Progressionmedicine.symptomHydroxymethylglutaryl-CoA Reductase InhibitorsClaudicationbusinessmedicine.drugArchives of medical research
researchProduct

Safety and Effectiveness of Paclitaxel Drug-Coated Devices in Peripheral Artery Revascularization

2021

Abstract Background Paclitaxel drug-coated devices (DCDs) were developed to improve lower extremity revascularization (LER) patency in peripheral artery disease (PAD) but have been associated with long-term mortality. Objectives This study assessed DCD safety and effectiveness in LER for PAD. Methods VOYAGER PAD (Vascular Outcomes Study of ASA [acetylsalicylic acid] Along with Rivaroxaban in Endovascular or Surgical Limb Revascularization for PAD) randomized patients with PAD who underwent LER to rivaroxaban or placebo. The primary VOYAGER PAD study efficacy and safety outcomes were composite cardiovascular and limb events and Thrombolysis In Myocardial Infarction major bleeding. For prespe…

Rivaroxabanmedicine.medical_specialtyProportional hazards modelbusiness.industrymedicine.medical_treatmentThrombolysisRevascularizationPlacebomedicine.diseasechemistry.chemical_compoundPaclitaxelchemistryInternal medicinemedicineCardiologyMyocardial infarctionmedicine.symptomCardiology and Cardiovascular MedicineClaudicationbusinessmedicine.drugJournal of the American College of Cardiology
researchProduct

Critical limb ischaemia: definition and natural hystory

2004

The term critical limb ischemia refers to a condition characterized by chronic ischemic at-rest pain, ulcers, or gangrene in one or both legs attributable to objectively proven arterial occlusive disease. Critical limb ischemia implies chronicity and is to be distinguished from acute limb ischemia. Its incidence is approximately 500 to 1000 per million year, with the highest rates among older subjects, smokers and diabetics. The rate of primary amputation ranges from 10% to 40%, and was performed only when no graftable distal vessels were present, or in neurologically impaired or hopelessly nonambulatory patients. Contrarily, in some highly specialized and aggressive centres about 90% of pa…

critical limb ischemiamedicine.medical_specialtyArteriosclerosismedicine.medical_treatmentRevascularizationAmputation SurgicalGangrenearterial occlusive diseaseIschemiaRisk Factorscardiovascular mortalityInternal medicinePeripheral arterial diseaseMedicineHumansMyocardial infarctionStrokePharmacologyGangrenePeripheral Vascular DiseasesLegbusiness.industryFootcardiovascular morbiditysurgical revascularizationHematologyCritical limb ischemiamedicine.diseaseIntermittent claudicationFontaine’s classificationSurgerybody regionsNatural historyAmputationrisk factors amputationCardiologyMolecular Medicinemedicine.symptomCardiology and Cardiovascular Medicinebusiness
researchProduct

Endovascular treatment of spontaneous isolated abdominal aortic dissection

2016

Isolated abdominal aortic dissection is a rare clinical disease representing only 1.3% of all dissections. There are a few case series reported in the literature. The causes of this pathology can be spontaneous, iatrogenic, or traumatic. Most patients are asymptomatic and symptoms are usually abdominal or back pain, while claudication and lower limb ischemia are rare. Surgical and endovascular treatment are two valid options with acceptable results. We herein describe nine cases of symptomatic spontaneous isolated abdominal aortic dissection, out of which four successfully were treated with an endovascular approach between July 2003 and July 2013. All patients were men, smokers, symptomati…

lcsh:Medical physics. Medical radiology. Nuclear medicinemedicine.medical_specialtymedicine.medical_treatmentlcsh:R895-920endovascular techniqueCase Report030204 cardiovascular system & hematologystent graftAsymptomaticSettore MED/22 - Chirurgia Vascolare03 medical and health sciences0302 clinical medicinemedicine.arterymedicineBack pain030212 general & internal medicinecardiovascular diseasesAbdominal aortaComputed tomography angiographyAortic dissectionmedicine.diagnostic_testbusiness.industryAbdominal aortastent graftsStentAbdominal aorta; dissection; endovascular technique; stent grafts; stentsGeneral Medicinemedicine.diseaseSurgeryDissectiondissectionstentsmedicine.symptomClaudicationbusiness
researchProduct

Cilostazol and atherogenic dyslipidemia: a clinically relevant effect

2011

Cilostazol is a reversible, selective inhibitor of PDE3A able to significantly improve walking distance in patients with intermittent claudication. However, beyond its antiplatelet and vasodilator properties, cilostazol seems to have significant effects on atherogenic dyslipidemia.The effects of cilostazol on plasma lipids, lipoproteins, apolipoproteins and postprandial lipemia are reviewed. A literature search (using Medline and Scopus) was performed up to 24 October 2010. The authors also manually reviewed the references of selected articles for any pertinent material.Cilostazol is able to significantly lower plasma triglyceride levels, with a concomitant increase in high-density lipoprot…

medicine.medical_specialtyApolipoprotein BTetrazolescilostazol atherogenic dyslipidemiaPhosphodiesterase 3 InhibitorsPeripheral Arterial Diseasechemistry.chemical_compoundDiabetes mellitusInternal medicineHumansMedicinePharmacology (medical)DyslipidemiasPharmacologymedicine.diagnostic_testbiologybusiness.industryCholesterolGeneral MedicineAtherosclerosismedicine.diseaseLipidsCyclic Nucleotide Phosphodiesterases Type 3Intermittent claudicationCilostazolCilostazolPostprandialEndocrinologyDiabetes Mellitus Type 2chemistrybiology.proteinlipids (amino acids peptides and proteins)medicine.symptombusinessLipid profileLipoproteinmedicine.drug
researchProduct

Tocilizumab therapy for unresponsive pulmonary arterial hypertension in a patient with Takayasu arteritis

2016

A 46-year-old female Caucasian patient was referred to our unit with upper extremity claudication, dyspnoea [New York Heart Association (NYHA) Class III], and weight loss. On physical examination, ...

medicine.medical_specialtyHypertension PulmonaryAntibodieTakayasu arteritisImmunologyPhysical examinationClass iiiTakayasu ArteritiAntibodies Monoclonal HumanizedTocilizumab therapyNew york heart association03 medical and health sciences0302 clinical medicineAntibodies Monoclonal Humanized; Female; Humans; Hypertension Pulmonary; Middle Aged; Takayasu Arteritis; Immunology and Allergy; Rheumatology; Immunology; Medicine (all)RheumatologyWeight lossInternal medicineMonoclonalmedicineImmunology and AllergyHumanized030203 arthritis & rheumatologymedicine.diagnostic_testbusiness.industryMedicine (all)General MedicinePulmonaryMiddle Agedmedicine.diseasePulmonary hypertensionSettore MED/16 - ReumatologiaHypertensionCardiologyFemalemedicine.symptomClaudicationbusiness030217 neurology & neurosurgeryHuman
researchProduct

2 Caregiver burden and health status perception of family caregivers of patients receiving palliative care at home

2020

Introduction The aim of this study was to explore the repercussions associated with caregiving of patients who receive palliative care at home due to an oncological disease through the assessment of the health status self-perception in the last year, the presence of anxiety and depressive symptoms and the assessment of caregiving burden. Method Design: Descriptive, cross-sectional study. Sample: family caregivers of patients with oncological disease who are under the follow-up of a home palliative care program hospital-based. Period: July 2015 and December 2016. Analysis: descriptive statistics. Questionnaires: Goldberg anxiety and depression scale; Zarit Caregiver Overload Scale in reduced…

medicine.medical_specialtyPalliative careDescriptive statisticsbusiness.industryFamily caregiversCaregiver burdenDiseaseFamily medicinemedicineAnxietymedicine.symptombusinessClaudicationDepression (differential diagnoses)Poster presentations
researchProduct